We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
45 hedge funds and large institutions have $91M invested in Corvus Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
1.44% less ownership
Funds ownership: 84.44% → 83% (-1.4%)
9% less capital invested
Capital invested by funds: $99.5M → $91M (-$8.58M)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
22% less funds holding
Funds holding: 58 → 45 (-13)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Holders
45
Holders Change
-13
Holders Change %
-22.41%
% of All Funds
0.98%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
6
Increased
14
Reduced
16
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.61M |
| 2 |
O
OrbiMed
New York
|
+$2.34M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$234K |
| 4 |
Millennium Management
New York
|
+$219K |
| 5 |
Renaissance Technologies
New York
|
+$201K |
Top Sellers
| 1 |
BlackRock
New York
|
-$2.31M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$798K |
| 4 |
State Street
Boston,
Massachusetts
|
-$751K |
| 5 |
JP Morgan Chase
New York
|
-$393K |
